Retrophin's Focus Shifts After Phase III PKAN Drug's Failure

 
• By Joseph Haas
Child-Sorrow
Retrophin misses its Phase III endpoint in PKAN, which typically manifests in childhood

More from Clinical Trials

More from R&D